Our Assembly-Line Future?
By Stuart A. Newman,
Counterpunch
| 07. 31. 2018
Human civilization has taken an important turn with the publication of a new report by the Nuffield Council, the semi-official bioethics agency of the United Kingdom. The document, two years in preparation, gives the go-ahead to genetically engineer human beings at the embryonic stages of development. The report stated: “There is potential for heritable genome editing interventions to be used at some point in the future in assisted human reproduction, as a means for people to secure certain characteristics in their children.” If history is a guide, the U.S. will not lag far behind the U.K. in following this dangerous path.
The U.K. pioneered human genetic engineering by approving, earlier this year, a technique to construct embryos using parts of the eggs of two different women, along with a man’s sperm, to create “three-person embryos.” Though deceptively promoted as “mitochondrial transfer,” the procedure really involves transferring around 20 thousand genes from a woman with impaired mitochondria into another woman’s egg. The accurate “three-person” designation was only widely used in the scientific literature after the procedure became legal. Similar misrepresentations of...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...